Intravascular ultrasound predictors of long-term outcomes following ABSORB bioresorbable scaffold implantation: A pooled analysis of the ABSORB III and ABSORB Japan trials

被引:3
|
作者
Nishi, Takeshi [1 ]
Okada, Kozo [1 ]
Kitahara, Hideki [1 ]
Kameda, Ryo [1 ]
Ikutomi, Masayasu [1 ]
Imura, Shinji [1 ]
Hollak, M. Brooke [1 ]
Yock, Paul G. [1 ]
Popma, Jeffrey J. [2 ]
Kusano, Hajime [3 ]
Cheong, Wai-Fung [3 ]
Sudhir, Krishnankutty [3 ]
Fitzgerald, Peter J. [1 ]
Ellis, Stephen G. [4 ]
Kereiakes, Dean J. [5 ]
Stone, Gregg W. [6 ,7 ]
Honda, Yasuhiro [1 ]
Kimura, Takeshi [8 ]
机构
[1] Stanford Univ, Sch Med, Stanford Cardiovasc Inst, Div Cardiovasc Med, Stanford, CA 94305 USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[3] Abbott Vasc, Clin Sci & Med Affairs, Santa Clara, CA USA
[4] Cleveland Clin, Dept Cardiovasc Med, Heart & Vasc Inst, Cleveland, OH 44106 USA
[5] Christ Hosp Heart & Vasc Ctr, Lindner Res Ctr, Cincinnati, OH USA
[6] Cardiovasc Res Fdn, New York, NY USA
[7] Icahn Sch Med Mt Sinai, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA
[8] Kyoto Univ Hosp, Dept Cardiovasc Med, Kyoto, Japan
关键词
Intravascular ultrasound; Bioresorbable vascular scaffold; Drug-eluting stent; CORONARY-ARTERY-DISEASE; ELUTING STENT; CLINICAL-OUTCOMES; THROMBOSIS; STENOSIS; IMPACT;
D O I
10.1016/j.jjcc.2021.03.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The long-term prognostic impact of IVUS findings following Absorb BVS implantation re-mains uncertain. This study aimed to identify the IVUS predictors of long-term clinical outcomes follow-ing ABSORB bioresorbable vascular scaffold (BVS) implantation from the pooled IVUS substudy cohorts of the ABSORB III and Japan trials. Methods: A total of 298 lesions in 286 patients were enrolled with 2:1 randomization to ABSORB BVS vs. cobalt-chromium everolimus-eluting stents. This sub-analysis included 168 lesions of 160 patients in the Absorb arm whose post-procedural quantitative IVUS were available. The primary endpoint of this analysis was device-oriented composite endpoint (DOCE) of target lesion failure, including cardiac death, target vessel-related myocardial infarction, or ischemia-driven target lesion revascularization. The median follow-up duration was 4.9 [3.1-5.0] years. Results: During follow-up, DOCE occurred in 10.1% of lesions treated with Absorb BVS. Among several post-procedural IVUS indices associated with DOCE, non-uniform device expansion (defined as unifor-mity index = minimum / maximum device area) (hazard ratio 0.47 per 0.1 increase [95%CI 0.28 to 0.77]; p = 0.003) and residual reference plaque burden (hazard ratio 4.01 per 10% increase [95%CI 1.50 to 10.77]; p = 0.006) were identified as independent predictors of DOCE by Cox multivariable analysis. Conclusions: Nonuniform device expansion and substantial untreated residual plaque in reference seg-ments were associated with long-term adverse events following BVS implantation. Baseline imaging to identify the appropriate device landing zone and procedural imaging to achieve uniform device expan-sion if possible (e.g. through post-dilatation) may improve clinical outcomes of BVS implantation. Clinical trial registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01751906 (ABSORB III); NCT01844284 (ABSORB Japan). (c) 2021 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:224 / 229
页数:6
相关论文
共 50 条
  • [21] BIORESORBABLE SCAFFOLD FOR TREATMENT OF CORONARY ARTERY LESIONS: FINAL INTRAVASCULAR ULTRASOUND RESULTS FROM THE ABSORB JAPAN TRIAL
    Okada, Kozo
    Honda, Yasuhiro
    Kitahara, Hideki
    Ikutomi, Masayasu
    Kameda, Ryo
    Hollak, M. Brooke
    Yock, Paul
    Kusano, Hajime
    Cheong, Wai-Fung
    Sudhir, Krishnan
    Fitzgerald, Peter
    Kimura, Takeshi
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 1020 - 1020
  • [22] Clinical outcomes following complete bioresorption of the Absorb everolimus-eluting bioresorbable scaffold: Four-year results from the ABSORB III trial
    Kereiakes, Dean
    Ellis, Stephen
    Stone, Gregg
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (13) : B27 - B27
  • [23] Impact of Peri-scaffold Plaque Burden on Long-term Arterial Response and Target Lesion Failure Following Absorb Bioresorbable Scaffold Implantation
    Nishi, Takeshi
    Okada, Kozo
    Kitahara, Hideki
    Kameda, Ryo
    Ikutomi, Masayasu
    Hollak, Brooke
    Yock, Paul G.
    Popma, Jeffrey J.
    Kusano, Hajime
    Cheong, Wai-Fung
    Sudhir, Krishna
    Fitzgerald, Peter
    Ellis, Stephen G.
    Kereiakes, Dean J.
    Stone, Gregg W.
    Honda, Yasuhiro
    Kimura, Takeshi
    CIRCULATION, 2019, 140
  • [24] Clinical Outcomes of the Absorb Everolimus-Eluting Bioresorbable Scaffold: Final 5-Year Results From the ABSORB III Trial
    Ellis, Stephen
    Kereiakes, Dean
    Stone, Gregg
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 74 (13) : B166 - B166
  • [25] 1-year Clinical Outcomes of Absorb Bioresorbable Vascular Scaffold (BVS) in Diabetic and Non-Diabetic Patients: Patient-Level Pooled Analysis from the ABSORB Randomized Trials
    Furer, Ariel
    Ben-Yehuda, Ori
    Redfors, Bjorn
    Serruys, Patrick
    Gao, Runlin
    Kimura, Takeshi
    Kereiakes, Dean
    Ellis, Stephen
    Zhao, Weiying
    Minh-Thien Vu
    Onuma, Yoshinobu
    Stone, Gregg
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (18) : B25 - B25
  • [26] Acute and long-term relocation of minimal lumen area after Absorb bioresorbable scaffold or Xience metallic stent implantation
    Katagiri, Y.
    Serruys, P. W.
    Tenekecioglu, E.
    Asano, T.
    Collet, C.
    Miyazaki, Y.
    Piek, J. J.
    Wykrzykowska, J.
    Chevalier, B.
    Mintz, G.
    Onuma, Y.
    EUROPEAN HEART JOURNAL, 2018, 39 : 1338 - 1338
  • [27] Relation between bioresorbable scaffold sizing using QCA-Dmax and long-term clinical outcomes in 1,232 patients from three study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II)
    Katagiri, Yuki
    Onuma, Yoshinobu
    Asano, Taku
    Chichareon, Ply
    Collet, Carlos
    Miyazaki, Yosuke
    Piek, Jan J.
    Wykrzykowska, Joanna J.
    Abizaid, Alexandre
    Ormiston, John A.
    Chevalier, Bernard
    Serruys, Patrick W.
    EUROINTERVENTION, 2018, 14 (09) : E1057 - E1066
  • [28] Attenuated-Signal Plaque and Long-Term Vessel Response after Bioresorbable Scaffold Implantation: IVUS Insights from the ABSORB JAPAN Trial
    Okada, Kozo
    Honda, Yasuhiro
    Kitahara, Hideki
    Kameda, Ryo
    Hollak, M. Brooke
    Yock, Paul G.
    Kusano, Hajime
    Cheong, Wai-Fung
    Sudhir, Krishna
    Kimura, Takeshi
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (13) : B68 - B68
  • [29] ImpaCt of an Optimal Implantation Strategy on Absorb Long-Term Outcomes: The CIAO Registry
    Rapetto, Claudio
    Leoncini, Massimo
    Cerrato, Enrico
    Regazzoli, Damiano
    Cortese, Bernardo
    Rossi, Angelica
    Fetiveau, Raffaela
    Geraci, Salvatore
    De Angelis, Maria Carmen
    Tespili, Maurizio
    Iannaccone, Mario
    Centola, Antonio
    Durante, Alessandro
    De Carlo, Marco
    De Caterina, Alberto
    Ribichini, Flavio
    Favaretto, Enrico
    Testa, Luca
    Pirisi, Raimondo
    Varbella, Ferdinando
    Nicolini, Elisa
    di Palma, Gaetano
    Loi, Bruno
    Poli, Arnaldo
    Caramanno, Giuseppe
    Varricchio, Attilio
    Garbo, Roberto
    Cuculo, Andrea
    Petronio, Anna Sonia
    Berti, Sergio
    Bollati, Mario
    Spedicato, Leonardo
    De Candia, Gianfranco
    Piva, Tommaso
    Quadri, Giorgio
    Colombo, Antonio
    Ielasi, Alfonso
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2021, 30 : 1 - 8
  • [30] Scaffold underexpansion and late lumen loss after bioresorbable scaffold implantation: Insights from ABSORB JAPAN trial
    Okada, Kozo
    Honda, Yasuhiro
    Kitahara, Hideki
    Ikutomi, Masayasu
    Kameda, Ryo
    Hollak, M. Brooke
    Yock, Paul G.
    Popma, Jeffrey J.
    Kusano, Hajime
    Cheong, Wai-Fung
    Sudhir, Krishnankutty
    Fitzgerald, Peter J.
    Kimura, Takeshi
    IJC HEART & VASCULATURE, 2020, 31